182 related articles for article (PubMed ID: 28511909)
21. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin.
Iqbal MA; Bamezai RN
PLoS One; 2012; 7(5):e36764. PubMed ID: 22574221
[TBL] [Abstract][Full Text] [Related]
22. Serine is a natural ligand and allosteric activator of pyruvate kinase M2.
Chaneton B; Hillmann P; Zheng L; Martin ACL; Maddocks ODK; Chokkathukalam A; Coyle JE; Jankevics A; Holding FP; Vousden KH; Frezza C; O'Reilly M; Gottlieb E
Nature; 2012 Nov; 491(7424):458-462. PubMed ID: 23064226
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study.
Marciniec K; Rzepka Z; Chrobak E; Boryczka S; Latocha M; Wrześniok D; Beberok A
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985481
[TBL] [Abstract][Full Text] [Related]
24. A review on the emerging roles of pyruvate kinase M2 in anti-leukemia therapy.
Yang GJ; Wu J; Leung CH; Ma DL; Chen J
Int J Biol Macromol; 2021 Dec; 193(Pt B):1499-1506. PubMed ID: 34740687
[TBL] [Abstract][Full Text] [Related]
25. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.
Mazurek S
Int J Biochem Cell Biol; 2011 Jul; 43(7):969-80. PubMed ID: 20156581
[TBL] [Abstract][Full Text] [Related]
26. Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment.
Sarfraz I; Rasul A; Jabeen F; Sultana T; Adem Ş
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296707
[TBL] [Abstract][Full Text] [Related]
27. Succinyl-5-aminoimidazole-4-carboxamide-1-ribose 5'-Phosphate (SAICAR) Activates Pyruvate Kinase Isoform M2 (PKM2) in Its Dimeric Form.
Yan M; Chakravarthy S; Tokuda JM; Pollack L; Bowman GD; Lee YS
Biochemistry; 2016 Aug; 55(33):4731-6. PubMed ID: 27481063
[TBL] [Abstract][Full Text] [Related]
28. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
[TBL] [Abstract][Full Text] [Related]
29. Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells.
Park JH; Kundu A; Lee SH; Jiang C; Lee SH; Kim YS; Kyung SY; Park SH; Kim HS
Int J Biol Sci; 2021; 17(8):1895-1908. PubMed ID: 34131394
[TBL] [Abstract][Full Text] [Related]
30. Identification of small molecule inhibitors of pyruvate kinase M2.
Vander Heiden MG; Christofk HR; Schuman E; Subtelny AO; Sharfi H; Harlow EE; Xian J; Cantley LC
Biochem Pharmacol; 2010 Apr; 79(8):1118-24. PubMed ID: 20005212
[TBL] [Abstract][Full Text] [Related]
31. A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia.
Kim DJ; Park YS; Kim ND; Min SH; You YM; Jung Y; Koo H; Noh H; Kim JA; Park KC; Yeom YI
Mol Cells; 2015 Apr; 38(4):373-9. PubMed ID: 25813626
[TBL] [Abstract][Full Text] [Related]
32. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
33. Drug design and testing: profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay.
Griffiths M; Sundaram H
Methods Mol Biol; 2011; 731():451-65. PubMed ID: 21516428
[TBL] [Abstract][Full Text] [Related]
34. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation.
Ye J; Mancuso A; Tong X; Ward PS; Fan J; Rabinowitz JD; Thompson CB
Proc Natl Acad Sci U S A; 2012 May; 109(18):6904-9. PubMed ID: 22509023
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
36. Activators of PKM2 in cancer metabolism.
Warner SL; Carpenter KJ; Bearss DJ
Future Med Chem; 2014 Jun; 6(10):1167-78. PubMed ID: 25078136
[TBL] [Abstract][Full Text] [Related]
37. Novel approach of fragment-based lead discovery applied to renin inhibitors.
Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
[TBL] [Abstract][Full Text] [Related]
38. Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture.
Dong T; Yan Y; Chai H; Chen S; Xiong X; Sun D; Yu Y; Deng L; Cheng F
Biomed Pharmacother; 2015 Feb; 69():277-84. PubMed ID: 25661370
[TBL] [Abstract][Full Text] [Related]
39. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC
PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
